UTHR Hedge Fund Ownership (Q2 2026)

United Therapeutics Corp Del (UTHR)

867 + Investors. Track Smart Money conviction in UTHR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — UTHR

Based on 878 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 5 quarters in a row

last 6Q

For 5 consecutive quarters, more hedge funds added UTHR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

878 hedge funds hold UTHR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +32% more funds vs a year ago

fund count last 6Q

+215 new funds entered over the past year (+32% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 51% buying

427 buying415 selling

Last quarter: 427 funds bought or added vs 415 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-17 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 114 → 200 → 123 → 106. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

55% of holders stayed for 2+ years

■ 55% conviction (2yr+) ■ 22% medium ■ 23% new

480 out of 878 hedge funds have held UTHR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💎

Buying through price weakness — shares +70%, value -11%

Value

-10%

+69%

Last quarter: funds added +70% more shares while total portfolio value only changed -11%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📊

Peak discovery — momentum slowing

87 → 114 → 200 → 123 → 106 new funds/Q

New funds entering each quarter: 114 → 200 → 123 → 106. UTHR is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

🏛️

Veteran-anchored — 60% veterans vs 27% newcomers

■ 60% veterans ■ 13% 1-2yr ■ 27% new

Entry-cohort mix of 893 holders: 533 (60%) are 2+ year veterans, 118 entered 1–2 years ago, and 242 (27%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 49% AUM from top-100 funds

49% from top-100 AUM funds

66 of 875 holders are among the 100 largest funds by AUM, controlling 49% of total institutional value in UTHR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.0

out of 10

Moderate Exit Risk

Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	867	854	1.52%
13F Shares	44M	45M	-3.67%
Total Value	$22.48B	$25.20B	-10.8%
New Positions	105	123	-18
Increased Positions	311	296	+15
Closed Positions	89	95	-6
Reduced Positions	329	321	+8
Total Calls	8	20	-60.0%
Total Puts	8	21	-61.9%
PUT/CALL Ratio	1.0	1.05	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

867

854

1.52%

13F Shares

44M

45M

-3.67%

Total Value

$22.48B

$25.20B

-10.8%

New Positions

105

123

-18

Increased Positions

311

296

+15

Closed Positions

-6

Reduced Positions

329

321

Total Calls

-60.0%

Total Puts

-61.9%

PUT/CALL Ratio

1.0

1.05

Neutral

Institutional Holders (2026 Q2)

867 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in UTHR. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 UTHR holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Avoro Capital Advisors LLC	13.52%	2,777,777	$1.51B
2	Eversept Partners, LP	8.09%	287,668	$155.9M
3	Vestal Point Capital, LP	5.51%	435,000	$235.7M
4	180 GPS Investments IC Ltd	5.50%	13,722	$7.4M
5	Nepsis Inc.	5.01%	27,273	$14.8M
6	First Turn Management, LLC	4.92%	84,932	$46.0M
7	Palo Alto Investors LP	4.69%	62,587	$33.9M
8	Soleus Capital Management, L.P.	4.21%	225,587	$122.2M
9	Summit Street Capital Management, LLC	4.01%	52,789	$28.6M
10	Nitorum Capital, L.P.	3.94%	10,664	$5.8M
11	Diadema Partners LP	3.63%	52,989	$28.7M
12	Tri Locum Partners LP	3.13%	47,026	$25.5M
13	Patient Square Capital LP	3.12%	37,120	$20.1M
14	Polaris Capital Management, LLC	2.73%	53,450	$29.0M
15	Illumine Investment Management, LLC	2.69%	—	$4.1M
16	Deerfield Management Company, L.P.	2.58%	457,000	$247.6M
17	Superstring Capital Management LP	2.45%	7,172	$3.9M
18	PFM Health Sciences, LP	2.32%	49,991	$27.1M
19	Persistent Asset Partners Ltd	2.26%	13,981	$7.6M
20	Bellevue Group AG	2.15%	188,515	$102.1M
21	Sofinnova Investments, Inc.	2.14%	76,489	$41.4M
22	Elmind Capital, LP	2.04%	15,000	$8.1M
23	Sidoxia Capital Management, LLC	1.97%	4,955	$2.7M
24	Sawgrass Asset Management LLC	1.89%	26,461	$14.3M
25	KVP Capital Advisors, LP	1.89%	4,750	$2.6M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — United Therapeutics Corp Del (UTHR)

What does the Smart Money Trend signal show for UTHR?

Buying streak — 5 quarters in a row: For 5 consecutive quarters, more hedge funds added UTHR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for UTHR?

Slight buying edge — 51% buying: Last quarter: 427 funds bought or added vs 415 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for UTHR holders?

Elite ownership — 49% AUM from top-100 funds: 66 of 875 holders are among the 100 largest funds by AUM, controlling 49% of total institutional value in UTHR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held UTHR?

55% of holders stayed for 2+ years: 480 out of 878 hedge funds have held UTHR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

United Therapeutics Corp Del (UTHR)

Smart Money Signals — UTHR

Buying streak — 5 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +32% more funds vs a year ago

Slight buying edge — 51% buying

Fewer new buyers each quarter (-17 vs last Q)

55% of holders stayed for 2+ years

Buying through price weakness — shares +70%, value -11%

Peak discovery — momentum slowing

Veteran-anchored — 60% veterans vs 27% newcomers

Elite ownership — 49% AUM from top-100 funds

Institutional Sentiment Summary — UTHR

Hedge Fund Ownership: UTHR

Market Analysis: UTHR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: UTHR

Hedge Fund Positioning: UTHR

Statistics: UTHR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — United Therapeutics Corp Del (UTHR)

Welcome to 13Foresight!